Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.64 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | CD4 | P01730 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799967 | 0.92 | BRD4 (0.67) | BRD4PTPN11GSK3BHTR6 | |
| SCHEMBL3409931 | 0.87 | BRD4 (0.53) | BRD4PTPN11L3MBTL1POLBALDH3A1 | |
| SCHEMBL17939298 | 0.86 | BRD4 (0.52) | BRD4PTPN11L3MBTL1POLBALDH3A1 | |
| SCHEMBL4163963 | 0.86 | PTPN11 (0.52) | BRD4PTPN11L3MBTL1POLBALDH3A1 | |
| SCHEMBL17939505 | 0.86 | BRD4 (0.52) | BRD4PTPN11L3MBTL1MAPT | |
| SCHEMBL15562621 | 0.85 | BRD4 (0.53) | BRD4PTPN11L3MBTL1POLBALDH3A1 | |
| SCHEMBL19250316 | 0.85 | BRD4 (0.54) | BRD4PTPN11L3MBTL1POLBALDH3A1 | |
| SCHEMBL1516645 | 0.85 | BRD4 (0.51) | BRD4PTPN11L3MBTL1POLBALDH3A1 | |
| SCHEMBL15555803 | 0.85 | BRD4 (0.51) | BRD4PTPN11ALDH1A1LMNAMAPT | |
| SCHEMBL4166790 | 0.84 | PTPN11 (0.52) | BRD4PTPN11L3MBTL1POLBALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3096761-A1 | SUBSTITUTED PYROOLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | Confluence Life Sciences, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9499551-B2 | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499551-B2 | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499551-B2 | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150210705-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210705-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210705-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015112854-A1 | SUBSTITUTED PYROOLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | CONFLUENCE LIFE SCIENCES, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| WO-2015112854-A1 | SUBSTITUTED PYROOLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | CONFLUENCE LIFE SCIENCES, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| EP-1765819-B1 | AZAINDOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-1765819-B1 | AZAINDOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-2325184-A1 | Azaindoles useful as inhibitors of protein kinases | Vertex Pharmceuticals Incorporated (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-1765819-A1 | AZAINDOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060122213-A1 | Azaindoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-06-08 | — | — | US | disclosed |
| WO-2006004984-A1 | AZAINDOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210705-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRAZINES FOR TREATING CANCER OR INFLAMMATORY DISEASES | TPMT, MALT1, IRAK4 | BRD4 42/4885PTPN11 1673/4885L3MBTL1 4318/4885 |
| US-20060122213-A1 | Azaindoles useful as inhibitors of protein kinases | PRKDC, ABL1, MAP3K20 | BRD4 627/4885PTPN11 757/4885L3MBTL1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.